Isodose surface volumes in cervix cancer brachytherapy: Change of practice from standard (Point A) to individualized image guided adaptive (EMBRACE I) brachytherapy

Radiotherapy and Oncology, Elsevier, ISSN 1879-0887

Volume 129, 3, 2018

DOI:10.1016/j.radonc.2018.09.002, Dimensions: pub.1107107354, PMID: 30243671,



  1. (1) Aarhus University Hospital, grid.154185.c, Central Denmark Region
  2. (2) McGill University Health Centre, grid.63984.30
  3. (3) Department of Radiation Oncology, Comprehensive Cancer Center, Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna/General Hospital of Vienna, Austria
  4. (4) University Medical Center Utrecht, grid.7692.a
  5. (5) Institut Gustave Roussy, grid.14925.3b
  6. (6) Tata Memorial Hospital, grid.410871.b
  7. (7) Institute of Oncology Ljubljana, grid.418872.0
  8. (8) Mount Vernon Hospital, grid.416188.2
  9. (9) Oslo University Hospital, grid.55325.34
  10. (10) University of Alberta, grid.17089.37
  11. (11) Post Graduate Institute of Medical Education and Research, grid.415131.3
  12. (12) St James's University Hospital, grid.443984.6
  13. (13) Radiotherapiegroep, Arnhem, The Netherlands
  14. (14) Universitair Ziekenhuis Leuven, grid.410569.f
  15. (15) University of Amsterdam, grid.7177.6
  16. (16) Norwegian University of Science and Technology, grid.5947.f
  17. (17) St Olav's University Hospital, grid.52522.32


PURPOSE: To investigate the isodose surface volumes (ISVs) for 85, 75 and 60 Gy EQD2 for locally advanced cervix cancer patients. MATERIALS AND METHODS: 1201 patients accrued in the EMBRACE I study were analysed. External beam radiotherapy (EBRT) with concomitant chemotherapy was followed by MR based image-guided adaptive brachytherapy (MR-IGABT). ISVs were calculated using a predictive model based on Total Reference Air Kerma and compared to Point A-standard loading systems. Influence of fractionation schemes and dose rates was evaluated through comparison of ISVs for α/β 10 Gy and 3 Gy. RESULTS: Median V85 Gy, V75 Gy and V60 Gy EQD210 were 72 cm3, 100 cm3 and 233 cm3, respectively. Median V85 Gy EQD210 was 23% smaller than in standard 85 Gy prescription to Point A. For small (<25 cm3), intermediate (25-35 cm3) and large (>35 cm3) CTVHR volumes, the V85 Gy was 57 cm3, 70 cm3 and 89 cm3, respectively. In 38% of EMBRACE patients the V85 Gy was similar to standard plans with 75-85 Gy to Point A. 41% of patients had V85 Gy smaller than standard plans receiving 75 Gy at Point A, while 21% of patients had V85 Gy larger than standard plans receiving 85 Gy at Point A. CONCLUSIONS: MR-IGABT and individualized dose prescription during EMBRACE I resulted in improved target dose coverage and decreased ISVs compared to standard plans used with classical Point A based brachytherapy. The ISVs depended strongly on CTVHR volume which demonstrates that dose adaptation was performed per individual tumour size and response during EBRT.


Research Categories

Main Subject Area

Fields of Research

Links & Metrics

NORA University Profiles

Aarhus University

Danish Open Access Indicator

2018: Unused

Research area: Medicine

Danish Bibliometrics Indicator

2018: Level 1

Research area: Medicine

Dimensions Citation Indicators

Times Cited: 11

Field Citation Ratio (FCR): 4.63

Relative Citation ratio (RCR): 1.33